Published in Neuropsychopharmacology on August 13, 2008
The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology (Berl) (2010) 2.19
Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug Alcohol Depend (2009) 2.03
Intracranial self-stimulation to evaluate abuse potential of drugs. Pharmacol Rev (2014) 1.37
Preclinical Determinants of Drug Choice under Concurrent Schedules of Drug Self-Administration. Adv Pharmacol Sci (2012) 1.34
Role of corticotropin-releasing factor in drug addiction: potential for pharmacological intervention. CNS Drugs (2011) 1.15
Extended heroin access increases heroin choices over a potent nondrug alternative. Neuropsychopharmacology (2013) 1.06
Drug-induced and genetic alterations in stress-responsive systems: Implications for specific addictive diseases. Brain Res (2009) 1.01
Effects of extended cocaine access and cocaine withdrawal on choice between cocaine and food in rhesus monkeys. Neuropsychopharmacology (2010) 1.00
Agonist replacement therapy for cocaine dependence: a translational review. Future Med Chem (2012) 0.97
Self administration of heroin and cocaine in morphine-dependent and morphine-withdrawn rhesus monkeys. Psychopharmacology (Berl) (2009) 0.94
Cocaine abstinence alters nucleus accumbens firing dynamics during goal-directed behaviors for cocaine and sucrose. Eur J Neurosci (2012) 0.91
Effects of the delta-opioid agonist SNC80 on the abuse liability of methadone in rhesus monkeys: a behavioral economic analysis. Psychopharmacology (Berl) (2011) 0.90
Abuse-related effects of µ-opioid analgesics in an assay of intracranial self-stimulation in rats: modulation by chronic morphine exposure. Behav Pharmacol (2013) 0.89
Medications development for opioid abuse. Cold Spring Harb Perspect Med (2013) 0.86
Effects of alterations in cannabinoid signaling, alone and in combination with morphine, on pain-elicited and pain-suppressed behavior in mice. J Pharmacol Exp Ther (2012) 0.86
Measuring the incentive value of escalating doses of heroin in heroin-dependent Fischer rats during acute spontaneous withdrawal. Psychopharmacology (Berl) (2011) 0.86
Effects of morphine on pain-elicited and pain-suppressed behavior in CB1 knockout and wildtype mice. Psychopharmacology (Berl) (2011) 0.85
Reinforcer-dependent enhancement of operant responding in opioid-withdrawn rats. Psychopharmacology (Berl) (2010) 0.81
Tolerance and sensitization to chronic escalating dose heroin following extended withdrawal in Fischer rats: possible role of mu-opioid receptors. Psychopharmacology (Berl) (2012) 0.81
Effects of repeated morphine on intracranial self-stimulation in male rats in the absence or presence of a noxious pain stimulus. Exp Clin Psychopharmacol (2015) 0.80
The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers. Addict Biol (2015) 0.80
Insights from Preclinical Choice Models on Treating Drug Addiction. Trends Pharmacol Sci (2016) 0.76
Effects of continuous nicotine treatment and subsequent termination on cocaine versus food choice in male rhesus monkeys. Exp Clin Psychopharmacol (2015) 0.75
Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology (2001) 9.25
Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse (2001) 4.03
Economic demand and essential value. Psychol Rev (2008) 3.85
Neurobiological mechanisms in the transition from drug use to drug dependence. Neurosci Biobehav Rev (2004) 2.97
Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. Neuropsychopharmacology (2007) 2.61
Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion. Nature (2000) 2.38
Rapid assessment of choice between cocaine and food in rhesus monkeys: effects of environmental manipulations and treatment with d-amphetamine and flupenthixol. Neuropsychopharmacology (2003) 2.23
Principles of drug abuse liability assessment in laboratory animals. Drug Alcohol Depend (2003) 1.71
MORPHINE SELF-ADMINISTRATION, FOOD-REINFORCED, AND AVOIDANCE BEHAVIORS IN RHESUS MONKEYS. Psychopharmacologia (1964) 1.44
Choice between heroin and food in nondependent and heroin-dependent rhesus monkeys: effects of naloxone, buprenorphine, and methadone. J Pharmacol Exp Ther (2006) 1.43
Suppression of corticotropin-releasing factor in the amygdala attenuates aversive consequences of morphine withdrawal. Behav Pharmacol (1995) 1.36
Role of different brain structures in the expression of the physical morphine withdrawal syndrome. J Pharmacol Exp Ther (1992) 1.29
Nucleus accumbens and amygdala are possible substrates for the aversive stimulus effects of opiate withdrawal. Neuroscience (1990) 1.28
Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats. Neuropsychopharmacology (2005) 1.23
Neural correlates of the motivational and somatic components of naloxone-precipitated morphine withdrawal. Eur J Neurosci (2002) 1.21
Behavioral and molecular effects of dopamine D1 receptor stimulation during naloxone-precipitated morphine withdrawal. J Neurosci (2006) 1.17
Profound depression of mesolimbic dopamine release after morphine withdrawal in dependent rats. Eur J Pharmacol (1991) 1.10
Discrete-trial choice procedure: effects of naloxone and methadone on choice between food and heroin. Pharmacol Rev (1975) 1.10
Kappa opioid antagonist effects of the novel kappa antagonist 5'-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys. Psychopharmacology (Berl) (2002) 1.09
Precipitation of morphine withdrawal syndrome in rats by administration of mu-, delta- and kappa-selective opioid antagonists. Neuropharmacology (1992) 1.05
Clonidine in morphine withdrawal. Differential effects on signs and symptoms. Arch Gen Psychiatry (1985) 1.05
Choice between food and heroin: effects of morphine, naloxone, and secobarbital. J Exp Anal Behav (1981) 1.05
Effects of mu-opioid agonists on cocaine- and food-maintained responding and cocaine discrimination in rhesus monkeys: role of mu-agonist efficacy. J Pharmacol Exp Ther (2002) 1.02
Interactions between the reinforcing effects of cocaine and heroin in a drug-vs-food choice procedure in rhesus monkeys: a dose-addition analysis. Psychopharmacology (Berl) (2005) 1.02
Effects of chronic methadone treatment on cocaine- and food-maintained responding under second-order, progressive-ratio and concurrent-choice schedules in rhesus monkeys. Drug Alcohol Depend (2004) 0.99
Role of corticotropin-releasing factor receptor-1 in opiate withdrawal. J Neurochem (2000) 0.98
Differential roles of corticotropin-releasing factor receptor subtypes 1 and 2 in opiate withdrawal and in relapse to opiate dependence. Eur J Neurosci (2000) 0.98
Clonidine blocks acquisition but not expression of conditioned opiate withdrawal in rats. Neuropsychopharmacology (1998) 0.97
Central noradrenergic neurons: a locus for the functional interplay between alpha-2 adrenoceptors and opiate receptors. J Clin Psychiatry (1982) 0.96
Corticotropin-releasing hormone antagonists, astressin B and antalarmin: differing profiles of activity in rhesus monkeys. Neuropsychopharmacology (2004) 0.96
Noradrenergic hyperactivity in opiate withdrawal supported by clonidine reversal of opiate withdrawal. Am J Psychiatry (1979) 0.95
Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans. Addiction (2003) 0.94
The primate locus coeruleus and effects of clonidine on opiate withdrawal. J Clin Psychiatry (1982) 0.91
Substitution and primary dependence studies in animals. Drug Alcohol Depend (1985) 0.91
Effects of clonidine on morphine withdrawal signs in the rat. Eur J Pharmacol (1975) 0.90
Heroin self-administration in dependent Wistar rats: increased sensitivity to naloxone. Psychopharmacology (Berl) (1999) 0.90
Discriminative stimulus effects of naltrexone in morphine-treated rhesus monkeys. J Pharmacol Exp Ther (1989) 0.90
A behavioral economic analysis of concurrent ethanol- and water-reinforced responding in different preference conditions. Alcohol Clin Exp Res (2000) 0.89
Clonidine antagonizes naloxone-induced suppression of conditioned behavior and body weight loss in morphine-dependent rats. Pharmacol Biochem Behav (1978) 0.89
Effects of clonidine and morphine on opioid withdrawal in rhesus monkeys. Psychopharmacology (Berl) (1986) 0.88
The effects of morphine treatment and morphine withdrawal on the dynorphin and enkephalin systems in Sprague-Dawley rats. Psychopharmacology (Berl) (1995) 0.88
Morphine withdrawal produces differential effects on the rate of lever-pressing for brain self-stimulation in the hypothalamus and midbrain in rats. Pharmacol Biochem Behav (1983) 0.87
Discriminative stimulus effects of naltrexone in the morphine-dependent rat. J Pharmacol Exp Ther (1979) 0.87
The effect of morphine tolerance dependence and abstinence on immunoreactive dynorphin (1-13) levels in discrete brain regions, spinal cord, pituitary gland and peripheral tissues of the rat. Brain Res (1992) 0.87
Cocaine and other indirect-acting monoamine agonists differentially attenuate a naltrexone discriminative stimulus in morphine-treated rhesus monkeys. J Pharmacol Exp Ther (2003) 0.86
Neurochemical substrates for opiate reinforcement. NIDA Res Monogr (1986) 0.85
The CRF1 receptor antagonist, R121919, attenuates the severity of precipitated morphine withdrawal. Eur J Pharmacol (2007) 0.84
Monoaminergic drugs and directly observable signs of LAAM withdrawal in rhesus monkeys. Behav Pharmacol (2005) 0.84
Cocaine and amphetamine attenuate the discriminative stimulus effects of naltrexone in opioid-dependent rhesus monkeys. J Pharmacol Exp Ther (2002) 0.83
Drug dependence studies in laboratory animals. NIDA Res Monogr (1978) 0.83
Effects of the CRF1 antagonist antalarmin on cocaine self-administration and discrimination in rhesus monkeys. Pharmacol Biochem Behav (2006) 0.83
Rapid neuroadaptation in the nucleus accumbens and bed nucleus of the stria terminalis mediates suppression of operant responding during withdrawal from acute opioid dependence. Neuroscience (2006) 0.83
Low dose naltrexone administration in morphine dependent rats attenuates withdrawal-induced norepinephrine efflux in forebrain. Prog Neuropsychopharmacol Biol Psychiatry (2008) 0.83
Use of cocaine to prevent opiate withdrawal. Am J Psychiatry (1992) 0.82
Precipitated morphine withdrawal in rats as a tool in opiate research. Curr Dev Psychopharmacol (1977) 0.80
Cocaine abuse and opioid withdrawal. Lancet (1989) 0.80
ICV administration of CRF blocker (CRF9-41 delta helical) reduces morphine withdrawal in rats. Prog Neuropsychopharmacol Biol Psychiatry (1998) 0.76
EVALUATION OF DRUG ABUSE TREATMENT MEDICATIONS: CONCORDANCE BETWEEN CLINICAL AND PRECLINICAL STUDIES. NIDA Res Monogr (2005) 0.76
Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A (2002) 4.34
The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci (2009) 3.06
Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab (2012) 2.76
Corticotropin-releasing factor 1 antagonists selectively reduce ethanol self-administration in ethanol-dependent rats. Biol Psychiatry (2006) 2.70
Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur J Neurosci (2008) 2.65
Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. ScientificWorldJournal (2007) 2.43
Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun (2009) 2.19
Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists. Psychopharmacology (Berl) (2007) 1.94
Stress-induced relapse to cocaine seeking: roles for the CRF(2) receptor and CRF-binding protein in the ventral tegmental area of the rat. Psychopharmacology (Berl) (2007) 1.86
The CRF1 receptor antagonist antalarmin attenuates yohimbine-induced increases in operant alcohol self-administration and reinstatement of alcohol seeking in rats. Psychopharmacology (Berl) (2007) 1.74
Cannabinoid potentiation of glycine receptors contributes to cannabis-induced analgesia. Nat Chem Biol (2011) 1.70
The anxiogenic drug yohimbine reinstates palatable food seeking in a rat relapse model: a role of CRF1 receptors. Neuropsychopharmacology (2005) 1.68
Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol Rev (2011) 1.66
In vivo effects of abused 'bath salt' constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: drug discrimination, thermoregulation, and locomotor activity. Neuropsychopharmacology (2012) 1.61
Reversal of pancreatitis-induced pain by an orally available, small molecule interleukin-6 receptor antagonist. Pain (2010) 1.58
CRF system recruitment mediates dark side of compulsive eating. Proc Natl Acad Sci U S A (2009) 1.57
Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats. Neuropsychopharmacology (2002) 1.45
Dissociation between opioid and CRF1 antagonist sensitive drinking in Sardinian alcohol-preferring rats. Psychopharmacology (Berl) (2006) 1.37
Synthesis and pharmacological effects of the enantiomers of the N-phenethyl analogues of the ortho and para e- and f-oxide-bridged phenylmorphans. Org Biomol Chem (2008) 1.36
Delta-opioid agonists: differential efficacy and potency of SNC80, its 3-OH (SNC86) and 3-desoxy (SNC162) derivatives in Sprague-Dawley rats. J Pharmacol Exp Ther (2004) 1.25
Synthesis of rac-(1R,4aR,9aR)-2-methyl-1,3,4,9a-tetrahydro-2H-1,4a-propanobenzofuro[2,3-c]pyridin-6-ol. An unusual double rearrangement leading to the ortho- and para-f oxide-bridged phenylmorphan isomers. Org Biomol Chem (2004) 1.25
Effects of dopamine transporter inhibitors on cocaine self-administration in rhesus monkeys: relationship to transporter occupancy determined by positron emission tomography neuroimaging. J Pharmacol Exp Ther (2004) 1.24
Corticotropin-releasing factor-1 receptor antagonists decrease heroin self-administration in long- but not short-access rats. Addict Biol (2009) 1.23
Opioid interactions in rhesus monkeys: effects of delta + mu and delta + kappa agonists on schedule-controlled responding and thermal nociception. J Pharmacol Exp Ther (2003) 1.21
Convulsant activity of a non-peptidic delta-opioid receptor agonist is not required for its antidepressant-like effects in Sprague-Dawley rats. Psychopharmacology (Berl) (2002) 1.18
Patterns of nicotinic receptor antagonism: nicotine discrimination studies. J Pharmacol Exp Ther (2011) 1.18
Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine ("ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice. Psychopharmacology (Berl) (2003) 1.17
Effect of chronic delivery of the Toll-like receptor 4 antagonist (+)-naltrexone on incubation of heroin craving. Biol Psychiatry (2013) 1.16
Comparison of receptor mechanisms and efficacy requirements for delta-agonist-induced convulsive activity and antinociception in mice. J Pharmacol Exp Ther (2002) 1.15
Effects of kappa opioids in an assay of pain-depressed intracranial self-stimulation in rats. Psychopharmacology (Berl) (2010) 1.14
Probes for narcotic receptor mediated phenomena. Part 28: new opioid antagonists from enantiomeric analogues of 5-(3-hydroxyphenyl)-N-phenylethylmorphan. Bioorg Med Chem (2002) 1.13
Opioid receptor-mediated hyperalgesia and antinociceptive tolerance induced by sustained opiate delivery. Neurosci Lett (2005) 1.13
Protracted withdrawal from alcohol and drugs of abuse impairs long-term potentiation of intrinsic excitability in the juxtacapsular bed nucleus of the stria terminalis. J Neurosci (2009) 1.12
Gonadal hormone modulation of mu, kappa, and delta opioid antinociception in male and female rats. J Pain (2005) 1.10
Opioid ligands with mixed properties from substituted enantiomeric N-phenethyl-5-phenylmorphans. Synthesis of a micro-agonist delta-antagonist and delta-inverse agonists. Org Biomol Chem (2007) 1.10
3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement. Psychopharmacology (Berl) (2002) 1.10
Role of the serotonin 5-HT2A receptor in the hyperlocomotive and hyperthermic effects of (+)-3,4-methylenedioxymethamphetamine. Psychopharmacology (Berl) (2004) 1.09
The selective non-peptidic delta opioid agonist SNC80 does not facilitate intracranial self-stimulation in rats. Eur J Pharmacol (2008) 1.09
Converging protein kinase pathways mediate adenylyl cyclase superactivation upon chronic delta-opioid agonist treatment. J Pharmacol Exp Ther (2003) 1.08
Inhibiting the TLR4-MyD88 signalling cascade by genetic or pharmacological strategies reduces acute alcohol-induced sedation and motor impairment in mice. Br J Pharmacol (2012) 1.07
Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats. Psychopharmacology (Berl) (2005) 1.07
Effects of selective dopaminergic compounds on a delay-discounting task. Behav Pharmacol (2011) 1.06
Synergism between a serotonin 5-HT2A receptor (5-HT2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addiction. ACS Chem Neurosci (2012) 1.06
The delta-opioid receptor agonist (+)BW373U86 regulates BDNF mRNA expression in rats. Neuropsychopharmacology (2004) 1.05
Nantenine: an antagonist of the behavioral and physiological effects of MDMA in mice. Psychopharmacology (Berl) (2004) 1.05
The sigma-receptor antagonist BD-1063 decreases ethanol intake and reinforcement in animal models of excessive drinking. Neuropsychopharmacology (2008) 1.04
The effects of CRF antagonists, antalarmin, CP154,526, LWH234, and R121919, in the forced swim test and on swim-induced increases in adrenocorticotropin in rats. Psychopharmacology (Berl) (2005) 1.04
Endogenous opioids upregulate brain-derived neurotrophic factor mRNA through delta- and micro-opioid receptors independent of antidepressant-like effects. Eur J Neurosci (2006) 1.04
Effects of peripherally restricted κ opioid receptor agonists on pain-related stimulation and depression of behavior in rats. J Pharmacol Exp Ther (2011) 1.03
Behavioral pharmacology of the mu/delta opioid glycopeptide MMP2200 in rhesus monkeys. J Pharmacol Exp Ther (2008) 1.03
Presynaptic CRF1 receptors mediate the ethanol enhancement of GABAergic transmission in the mouse central amygdala. ScientificWorldJournal (2009) 1.03
Corticotropin-releasing factor receptor-dependent effects of repeated stress on tau phosphorylation, solubility, and aggregation. Proc Natl Acad Sci U S A (2012) 1.02
Separation of the convulsions and antidepressant-like effects produced by the delta-opioid agonist SNC80 in rats. Psychopharmacology (Berl) (2005) 1.02
Antagonism of sigma-1 receptors blocks compulsive-like eating. Neuropsychopharmacology (2012) 1.01
(+)-naloxone, an opioid-inactive toll-like receptor 4 signaling inhibitor, reverses multiple models of chronic neuropathic pain in rats. J Pain (2012) 1.00
Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors. J Pharmacol Exp Ther (2003) 1.00
A novel and facile preparation of bremazocine enantiomers through optically pure N-norbremazocines. Bioorg Med Chem (2004) 1.00
Recombinant cannabinoid type 2 receptor in liposome model activates g protein in response to anionic lipid constituents. J Biol Chem (2011) 0.99
Stress-induced potentiation of cocaine reward: a role for CRF R1 and CREB. Neuropsychopharmacology (2009) 0.99
Behavioral effects of delta-opioid receptor agonists: potential antidepressants? Jpn J Pharmacol (2002) 0.99
Activation of σ-receptors induces binge-like drinking in Sardinian alcohol-preferring rats. Neuropsychopharmacology (2011) 0.98
Liposomes containing monophosphoryl lipid A: a potent adjuvant system for inducing antibodies to heroin hapten analogs. Vaccine (2013) 0.98
Identification of a novel "almost neutral" micro-opioid receptor antagonist in CHO cells expressing the cloned human mu-opioid receptor. Synapse (2010) 0.97
Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane in rhesus monkeys. J Pharmacol Exp Ther (2007) 0.97
Neuropeptide deficient mice have attenuated nociceptive, vascular, and inflammatory changes in a tibia fracture model of complex regional pain syndrome. Mol Pain (2012) 0.96
Proerectile effects of dopamine D2-like agonists are mediated by the D3 receptor in rats and mice. J Pharmacol Exp Ther (2009) 0.96
Probes for narcotic receptor mediated phenomena. 44. Synthesis of an N-substituted 4-hydroxy-5-(3-hydroxyphenyl)morphan with high affinity and selective μ-antagonist activity. Eur J Med Chem (2012) 0.96
Corticotropin-releasing hormone antagonists, astressin B and antalarmin: differing profiles of activity in rhesus monkeys. Neuropsychopharmacology (2004) 0.96
Probes for narcotic receptor mediated phenomena. 39. Enantiomeric N-substituted benzofuro[2,3-c]pyridin-6-ols: synthesis and topological relationship to oxide-bridged phenylmorphans. J Med Chem (2009) 0.96
Stress-induced reinstatement of alcohol-seeking in rats is selectively suppressed by the neurokinin 1 (NK1) antagonist L822429. Psychopharmacology (Berl) (2011) 0.96
Differential behavioral tolerance to the delta-opioid agonist SNC80 ([(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in Sprague-Dawley rats. J Pharmacol Exp Ther (2005) 0.95
Restraint stress and ethanol consumption in two mouse strains. Alcohol Clin Exp Res (2008) 0.95
Serotonin (5-hydroxytryptamine) 5-HT(2A) receptor: association with inherent and cocaine-evoked behavioral disinhibition in rats. Behav Pharmacol (2011) 0.94
Increased agonist affinity at the μ-opioid receptor induced by prolonged agonist exposure. J Neurosci (2013) 0.94
Probes for narcotic receptor mediated phenomena. 40. N-substituted cis-4a-ethyl-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-8-ols. Bioorg Med Chem (2009) 0.94
Persistent antagonism of methamphetamine-induced dopamine release in rats pretreated with GBR12909 decanoate. J Pharmacol Exp Ther (2002) 0.93
The convulsive and electroencephalographic changes produced by nonpeptidic delta-opioid agonists in rats: comparison with pentylenetetrazol. J Pharmacol Exp Ther (2006) 0.93
Hallucinogen-like effects of N,N-dipropyltryptamine (DPT): possible mediation by serotonin 5-HT1A and 5-HT2A receptors in rodents. Pharmacol Biochem Behav (2007) 0.92
Studies of the biogenic amine transporters. XI. Identification of a 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR12909) analog that allosterically modulates the serotonin transporter. J Pharmacol Exp Ther (2005) 0.92
Clinically employed opioid analgesics produce antinociception via μ-δ opioid receptor heteromers in Rhesus monkeys. ACS Chem Neurosci (2012) 0.92
Electroencephalographic and convulsant effects of the delta opioid agonist SNC80 in rhesus monkeys. Pharmacol Biochem Behav (2006) 0.92
Corticotropin releasing hormone (CRH) antagonist attenuates adjuvant induced arthritis: role of CRH in peripheral inflammation. J Rheumatol (2002) 0.92
Glucuronic acid and the ethanol metabolite ethyl-glucuronide cause toll-like receptor 4 activation and enhanced pain. Brain Behav Immun (2013) 0.92
Selective serotonin 2A receptor antagonism attenuates the effects of amphetamine on arousal and dopamine overflow in non-human primates. J Sleep Res (2013) 0.91
Serotonin 5-HT2A receptors underlie increased motor behaviors induced in dopamine-depleted rats by intrastriatal 5-HT2A/2C agonism. J Pharmacol Exp Ther (2004) 0.91
Role of delta opioid efficacy as a determinant of mu/delta opioid interactions in rhesus monkeys. Eur J Pharmacol (2008) 0.91
Location, structure, and dynamics of the synthetic cannabinoid ligand CP-55,940 in lipid bilayers. Biophys J (2009) 0.91
Effects of the δ opioid receptor agonist SNC80 on pain-related depression of intracranial self-stimulation (ICSS) in rats. J Pain (2012) 0.91
CRHR1 Receptor binding and lipophilicity of pyrrolopyrimidines, potential nonpeptide corticotropin-releasing hormone type 1 receptor antagonists. Bioorg Med Chem (2002) 0.91
Preclinical evaluation of GBR12909 decanoate as a long-acting medication for methamphetamine dependence. Ann N Y Acad Sci (2002) 0.90
Behavioral, adrenal, and sympathetic responses to long-term administration of an oral corticotropin-releasing hormone receptor antagonist in a primate stress paradigm. J Clin Endocrinol Metab (2004) 0.90
Effects of the delta-opioid agonist SNC80 on the abuse liability of methadone in rhesus monkeys: a behavioral economic analysis. Psychopharmacology (Berl) (2011) 0.90
Neurobiological changes mediating the effects of chronic fluoxetine on cocaine use. Neuropsychopharmacology (2012) 0.90
Probes for narcotic receptor mediated phenomena. 46. N-substituted-2,3,4,9,10,10a-hexahydro-1H-1,4a-(epiminoethano)phenanthren-6- and 8-ols - carbocyclic relatives of f-oxide-bridged phenylmorphans. Eur J Med Chem (2012) 0.90